Sairopa B.V. Information

Sairopa develops novel treatments for cancer by modulating the patient’s immune system. Early 2021 Sairopa acquired, backed by a reputable biotech investor, a portfolio of therapeutic antibodies from an American public company. Sairopa will enter clinical testing of two of its lead compounds in Phase 1 clinical trials in 2022. The company is based in Rotterdam, the Netherlands but operates internationally & virtually. To advance our programs, we are looking for a project manager that wants to make a difference and has a pioneer’s mentality.